Should you buy Tate & Lyle plc, QinetiQ Group plc and Paypoint plc following today’s updates?

Royston Wild considers whether investors should snap up Tate & Lyle plc (LON: TATE), QinetiQ Group plc (LON: QQ) and Paypoint plc (LON: PAY).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Today I’m looking at three Footsie stocks making headlines on Thursday.

Defence dynamo

Shares in defence giant QinetiQ (LSE: QQ) crept to two-and-half-month peaks this week in the lead-up to Thursday’s full-year results. And investor faith appears to have been rewarded even though the engineer saw revenues slip 1% during the 12 months to March 2016, to £755.7m, while pre-tax profit slumped 14% to £90.2m.

But QinetiQ’s sales outlook appears to be steadily improving, the company enjoying an 8% boost in its order book — to £659.8m — thanks to a £153m, five-year renewal contract with the Ministry of Defence for aircraft engineering support.

Furthermore, QinetiQ advised that 74% of revenues for fiscal 2017 were covered as of the start of April.

With defence budgets back on the mend, the City expects QinetiQ to enjoy an earnings advance of 1% in both 2017 and 2018, resulting in very-decent P/E ratios of 14.9 times and 14.6 times, respectively. And dividend yields of 2.6% for 2017 and 2.9 % for 2018 provide a handy-if-unspectacular sweetener.

Paying off

Payments specialist Paypoint (LSE: PAY) also enjoyed a bump in Thursday business, a 2% advance sending the stock to levels not seen since early January.

Paypoint advised that pre-tax profits careered 84% lower in the year to March 2016, to £8.2m, the business hammered by a £30.8m impairment on its outgoing mobile payments division.

Revenues at Paypoint slipped 3% during the period, to £212.6m, although the company remains bullish over its long-term outlook as it develops its retail services. Indeed, Paypoint saw the number of retail transactions shoot 17.8% higher last year, to 140m.

The number crunchers certainly believe Paypoint is on the way up, and have pencilled-in earnings rises of 20% and 7% for 2017 and 2018. These figures produce excellent P/E ratings of 13.4 times and 12.7 times.

And dividend hunters will no doubt be attracted by huge dividend yields of 5.4% for this year and 5.8% for 2018.

Too sweet

Sugar play Tate & Lyle (LSE: TATE) has proved one of the stars of the show on Thursday, the stock gaining 2% and reaching levels not seen since last April in the process.

Tate & Lyle announced that sales edged fractionally higher during the year to March, to £2.36bn, although investors cheered news that adjusted pre-tax profits nudged 5% higher to £193m.

The food play posted a mixed set of sales results. Revenues at its Specialty Food Ingredients arm nudging 4% higher from 2015, to £897m. But Tate & Lyle’s Bulk Ingredients arm continues to struggle, and sales here dipped 1% to £1.46bn.

The City expects restructuring at the sugar giant to keep driving earnings higher, and rises of 7% and 6% are expected in 2017 and 2018, resulting in P/E ratings of 16.6 times and 15.5 times.

However, dividend yields of 4.7% for this year and 4.8% for 2018 help to offset these middling multiples.

Still, I believe Tate & Lyle still has plenty of work ahead of it to turn around its Bulk Ingredients business, while adverse currency movements add a further headache for the business. I reckon the stock’s turnaround story still leaves plenty of questions to be answered.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Royston Wild has no position in any shares mentioned. The Motley Fool UK owns shares of PayPoint. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Publish Test

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut…

Read more »

Investing Articles

JP P-Press Update Test

Read more »

Investing Articles

JP Test as Author

Test content.

Read more »

Investing Articles

KM Test Post 2

Read more »

Investing Articles

JP Test PP Status

Test content. Test headline

Read more »

Investing Articles

KM Test Post

This is my content.

Read more »

Investing Articles

JP Tag Test

Read more »

Investing Articles

Testing testing one two three

Sample paragraph here, testing, test duplicate

Read more »